Molecular docking of compounds from Clinacanthus nutans extract detected by GC-MS analysis with the SARS-CoV-2 main protease and ACE2 protein

Nat Prod Res. 2022 Jun;36(11):2848-2852. doi: 10.1080/14786419.2021.1919104. Epub 2021 May 5.

Abstract

Clinacanthus nutans has been reported to have many medicinal properties and it is traditionally used in treating viral lesions. This study aims to determine the molecular docking of C. nutans compounds detected by Gas Chromatography-Mass Spectrometry (GC-MS) with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 main protease) protein and its host receptor angiotensin-converting enzyme 2 (ACE2) protein using the AutoDock 4.2 tool. The drug-likeness and molecular docking analyses showed that fourteen compounds of C. nutans satisfied the Lipinski's rule of five and they exhibited good inhibitory effects against the SARS-Cov-2 main protease and ACE2 proteins. In addition, the glyceryl 2-linolenate compound was found to have the most potent binding affinities with both proteins. The results provide useful insights into the molecular inhibitory interactions of C. nutans compounds detected by GC-MS analysis with the targeted SARS-CoV-2 main protease and ACE2 protein.

Keywords: Clinacanthus nutans; angiotensin-converting enzyme 2; molecular docking; severe acute respiratory syndrome coronavirus 2.

MeSH terms

  • Acanthaceae* / chemistry
  • Angiotensin-Converting Enzyme 2
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Coronavirus 3C Proteases
  • Gas Chromatography-Mass Spectrometry
  • Molecular Docking Simulation
  • Plant Extracts / pharmacology
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Plant Extracts
  • Angiotensin-Converting Enzyme 2
  • 3C-like proteinase, SARS-CoV-2
  • Coronavirus 3C Proteases